Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
NCT ID: NCT01703793
Last Updated: 2013-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
240 participants
INTERVENTIONAL
2012-09-30
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult
NCT03830177
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis
NCT02749383
A Clinical Study to Assess the Safety and Effectiveness of Scalp Cream for Symptom Relief and Microbiome Balance in Mild-moderate Seborrheic Dermatitis Patients.
NCT07063615
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
NCT01756898
Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp
NCT01137630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vehicle
Vehicle (placebo) treatment, twice a week for four weeks.
Vehicle (placebo)
Test Product 10156
Product 10156 treatment, twice a week for four weeks.
Test Product 10156
Test Product 49778
Product 49778 treatment, twice a week for four weeks.
Test Product 49778
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test Product 49778
Test Product 10156
Vehicle (placebo)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Additional criteria as identified in the protocol.
Exclusion Criteria
* History of or ongoing atopic dermatitis of the scalp.
* Additional criteria as identified in the protocol.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medicis Global Service Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ira Lawrence, MD
Role: STUDY_CHAIR
Medicis Pharmaceutical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fremont, California, United States
Los Angeles, California, United States
San Diego, California, United States
New Haven, Connecticut, United States
Aventura, Florida, United States
Augusta, Georgia, United States
Snellville, Georgia, United States
Evansville, Indiana, United States
Detroit, Michigan, United States
Fridley, Minnesota, United States
Paramus, New Jersey, United States
Mount Kisco, New York, United States
New York, New York, United States
High Point, North Carolina, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Arlington, Texas, United States
Austin, Texas, United States
College Station, Texas, United States
Plano, Texas, United States
Webster, Texas, United States
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP-1001-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.